drugset / Trial / NCT05416476

Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine

NCT05416476 ↗

RandomizedParallel-groupQuadruple-blindPrevention

Summary

In this study,288 adult migraine patients aged 18-65 years (diagnosed with migraine without aura and/or migraine with aura, with at least a 1-year history)will be collected to evaluate the efficacy, safety and tolerability of Anisodine Hydrobromide in preventing migraine attacks in episodic migraine in adults.

Timeline

Start
2023-10-30
Primary completion
2025-10-30
Completion
2025-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Anisodine Hydrobromide Small molecule 1 mg Oral